This open-label study (n=12) investigates the potential of psilocybin-assisted group therapy (PAT) in cancer patients suffering from depression. Participants underwent preparatory sessions, a high-dose (25mg) psilocybin group session, and integration sessions over three weeks, with clinical outcomes measured at baseline, two weeks, and 26 weeks post-intervention. Results show significant decreases in depression symptoms and no serious adverse events, suggesting safety, feasibility, and possible efficacy of the therapy.
- Published
- Journal
- Journal of Pain and Symptom Management
- Authors
- Lewis, B. R., Garland, E. L., Byrne, K., Durns, T., Hendrick, J., Beck, A., Thielking, P.